Swedish Orphan Biovitrum AB (MEX:SOBI N) Research & Development: MXN6,692 Mil (TTM As of Mar. 2026)


MEX:SOBI N Swedish Orphan Biovitrum AB MEX:SOBI N
86 GF Score
Price MXN523.55
GF Value MXN384.98
! 6 Warning Signs
View Full Analysis

What is Swedish Orphan Biovitrum AB Research & Development?

Swedish Orphan Biovitrum AB MEX:SOBI N 86 Research & Development is MXN6,692 Mil as of Mar. 2026. GuruFocus rates MEX:SOBI N with a GF Score™ of 86/100 and a GF Value™ of MXN384.98. The stock has 6 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Swedish Orphan Biovitrum AB's Research & Development for the three months ended in Mar. 2026 was MXN1,835 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN6,692 Mil.

Swedish Orphan Biovitrum AB  (MEX:SOBI N) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Swedish Orphan Biovitrum AB Research & Development Related Terms

Swedish Orphan Biovitrum AB Research & Development Historical Data

* Premium members only.

The historical data trend for Swedish Orphan Biovitrum AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Swedish Orphan Biovitrum AB Research & Development Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,500.19 4,422.20 4,626.81 6,717.11 6,426.53

Swedish Orphan Biovitrum AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,683.85 1,678.19 1,475.73 1,703.02 1,834.78
MEX:SOBI N
86GF Score
Swedish Orphan Biovitrum AB MEX:SOBI N
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Swedish Orphan Biovitrum AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN6,692 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN6,692 Mil mean?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a Research & Development of MXN6,692 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Swedish Orphan Biovitrum AB and its competitors.
Is Swedish Orphan Biovitrum AB's Research & Development too high?
Swedish Orphan Biovitrum AB's current Research & Development is MXN6,692 Mil. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 86/100, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Research & Development compare to ZTS and UTHR?
Swedish Orphan Biovitrum AB's Research & Development of MXN6,692 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Swedish Orphan Biovitrum AB and its competitors. Swedish Orphan Biovitrum AB's current Research & Development is MXN6,692 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Swedish Orphan Biovitrum AB (MEX:SOBI N) has a current Research & Development of MXN6,692 Mil. The stock's GF Value™ is MXN384.98, compared to a current price of MXN523.55 — trading 36% above its estimated fair value. The current Research & Development is MXN6,692 Mil. Swedish Orphan Biovitrum AB's overall GF Score™ is 86/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (MEX:SOBI N), the current Research & Development is MXN6,692 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Swedish Orphan Biovitrum AB (MEX:SOBI N) Overvalued in 2026?

Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued. The current stock price of MXN523.55 is trading 36% above its estimated GF Value™ of MXN384.98.

Key valuation signals for MEX:SOBI N:

  • Research & Development: MXN6,692 Mil
  • GF Value™: MXN384.98 vs. price of MXN523.55 (36% above fair value)
  • GF Score™: 86/100 with 6 warning signs

No single metric tells the full story. See the MEX:SOBI N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Swedish Orphan Biovitrum AB Business Description

Address Norra Stationsgatan 93A, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
86GF Score

Get the complete analysis for MEX:SOBI N

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN523.55
Price
MXN384.98
GF Value